KRAS and Patent ductus arteriosus: In the unadjusted analysis, patients with KRAS mutated vs. wild-type PDA had similar survival rates: median OS 14.5 vs. 13.4 months (P = .91), and median PFS 8.6 vs. 9.0 months (P = .30) with first-line systemic therapies.